From GlobeNewswire: 2024-04-03 16:05:00

Madrigal Pharmaceuticals, Inc. granted equity awards to 30 new employees on April 1, 2024, as part of their 2023 Inducement Plan. The awards included options to purchase 1,813 shares of common stock and 12,709 time-based restricted stock units, with an exercise price of $255.74 per share. Vesting of options occurs quarterly starting on the first anniversary of the grant date, while restricted stock units vest in increments over four years. These awards are contingent on continued employment. Madrigal Pharmaceuticals is focused on developing therapeutics for nonalcoholic steatohepatitis (NASH) with their medication, Rezdiffra (resmetirom). Visit www.madrigalpharma.com for more information.



Read more at GlobeNewswire: Madrigal Pharmaceuticals Reports Inducement Grants under